Tags

Type your tag names separated by a space and hit enter

The effects of lipid-lowering therapy on low-density lipoprotein auto-antibodies: relationship with low-density lipoprotein oxidation and plasma total antioxidant status.

Abstract

BACKGROUND

Oxidized low-density lipoprotein (Ox-LDL) is believed to play an important role in the progression of atherosclerosis. Oxidative modification of low-density lipoprotein (LDL) is a prerequisite for rapid accumulation of LDL in macrophages and for the formation of foam cells. Because of high antioxidant levels in plasma, LDL oxidation is suggested to occur mainly in the subendothelial space of the arterial wall, where there is the concomitant presence of large amounts of reactive oxygen species generated by endothelial cells and activated leukocytes. After Ox-LDL formation, antibodies against this form of LDL may occur. Auto-antibodies against Ox-LDL (AuAb-Ox-LDL) show directly in in-vivo LDL oxidation. Many studies have indicated that the amount of antibodies in serum is positively correlated to the rate of progression of atherosclerotic plaques.

DESIGN AND METHODS

In this study the effect of lipid-lowering therapy on the levels of AuAb-Ox-LDL in patients with dyslipidemia was determined using atorvastatin (10 mg/day), and the relationship between the antibodies and plasma total antioxidant status (TAS) and LDL oxidation capacity was also investigated. Serum levels of AuAb-Ox-LDL, lipids, lipoproteins, TAS and susceptibility of LDL to oxidation were determined using lag time in 44 patients with dyslipidemia (29 with hypercholesterolemia and 15 with mixed-type hyperlipidemia).

RESULTS

After lipid-lowering therapy, serum levels of AuAb-Ox-LDL were found to be significantly decreased, by 18.7%, while lag time and plasma TAS were increased (31.3% and 7.6% respectively) in patients with dyslipidemia. The percentage change in lag time was found to be negatively correlated to the percentage change in AuAb-Ox-LDL (r = -0.31, P < 0.05). The percentage change in lag time also showed a positive correlation with the percentage change in TAS (r = 0.58, P < 0.01). AuAb-Ox-LDL levels decreased by 21.7% in patients with hypercholesterolemia and by 12.6% in patients with mixed-type hyperlipidemia. Also AuAb-Ox-LDL levels in patients with hypercholesterolemia were higher than in those with mixed-type hyperlipidemia (367 +/- 294 compared with 300 +/- 176 mU/l).

CONCLUSION

It was concluded that lipid-lowering therapy may contribute to the reduction in levels of AuAb-Ox-LDL and the increase in the antioxidant capacity of plasma LDL and TAS. It was also suggested that the measurement of antibodies against Ox-LDL during lipid-lowering therapy may be used as an important marker for representing in-vivo LDL oxidation and atherosclerotic processes.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Cardiology, Karadeniz Technical University, Trabzon, Turkey. corem71@yahoo.com

    , , , ,

    Source

    Coronary artery disease 13:1 2002 Feb pg 65-71

    MeSH

    Adult
    Aged
    Antioxidants
    Apolipoproteins
    Arteriosclerosis
    Atorvastatin
    Autoantibodies
    Female
    Heptanoic Acids
    Humans
    Hyperlipidemias
    Hypolipidemic Agents
    Immunoassay
    Lipids
    Lipoproteins
    Lipoproteins, LDL
    Male
    Middle Aged
    Oxidation-Reduction
    Pyrroles

    Pub Type(s)

    Journal Article
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    11917201

    Citation

    Orem, Cihan, et al. "The Effects of Lipid-lowering Therapy On Low-density Lipoprotein Auto-antibodies: Relationship With Low-density Lipoprotein Oxidation and Plasma Total Antioxidant Status." Coronary Artery Disease, vol. 13, no. 1, 2002, pp. 65-71.
    Orem C, Orem A, Uydu HA, et al. The effects of lipid-lowering therapy on low-density lipoprotein auto-antibodies: relationship with low-density lipoprotein oxidation and plasma total antioxidant status. Coron Artery Dis. 2002;13(1):65-71.
    Orem, C., Orem, A., Uydu, H. A., Celik, S., Erdöl, C., & Kural, B. V. (2002). The effects of lipid-lowering therapy on low-density lipoprotein auto-antibodies: relationship with low-density lipoprotein oxidation and plasma total antioxidant status. Coronary Artery Disease, 13(1), pp. 65-71.
    Orem C, et al. The Effects of Lipid-lowering Therapy On Low-density Lipoprotein Auto-antibodies: Relationship With Low-density Lipoprotein Oxidation and Plasma Total Antioxidant Status. Coron Artery Dis. 2002;13(1):65-71. PubMed PMID: 11917201.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - The effects of lipid-lowering therapy on low-density lipoprotein auto-antibodies: relationship with low-density lipoprotein oxidation and plasma total antioxidant status. AU - Orem,Cihan, AU - Orem,Asim, AU - Uydu,Hüseyin Avni, AU - Celik,Sükrü, AU - Erdöl,Cevdet, AU - Kural,Birgül Vanizor, PY - 2002/3/28/pubmed PY - 2002/5/2/medline PY - 2002/3/28/entrez SP - 65 EP - 71 JF - Coronary artery disease JO - Coron. Artery Dis. VL - 13 IS - 1 N2 - BACKGROUND: Oxidized low-density lipoprotein (Ox-LDL) is believed to play an important role in the progression of atherosclerosis. Oxidative modification of low-density lipoprotein (LDL) is a prerequisite for rapid accumulation of LDL in macrophages and for the formation of foam cells. Because of high antioxidant levels in plasma, LDL oxidation is suggested to occur mainly in the subendothelial space of the arterial wall, where there is the concomitant presence of large amounts of reactive oxygen species generated by endothelial cells and activated leukocytes. After Ox-LDL formation, antibodies against this form of LDL may occur. Auto-antibodies against Ox-LDL (AuAb-Ox-LDL) show directly in in-vivo LDL oxidation. Many studies have indicated that the amount of antibodies in serum is positively correlated to the rate of progression of atherosclerotic plaques. DESIGN AND METHODS: In this study the effect of lipid-lowering therapy on the levels of AuAb-Ox-LDL in patients with dyslipidemia was determined using atorvastatin (10 mg/day), and the relationship between the antibodies and plasma total antioxidant status (TAS) and LDL oxidation capacity was also investigated. Serum levels of AuAb-Ox-LDL, lipids, lipoproteins, TAS and susceptibility of LDL to oxidation were determined using lag time in 44 patients with dyslipidemia (29 with hypercholesterolemia and 15 with mixed-type hyperlipidemia). RESULTS: After lipid-lowering therapy, serum levels of AuAb-Ox-LDL were found to be significantly decreased, by 18.7%, while lag time and plasma TAS were increased (31.3% and 7.6% respectively) in patients with dyslipidemia. The percentage change in lag time was found to be negatively correlated to the percentage change in AuAb-Ox-LDL (r = -0.31, P < 0.05). The percentage change in lag time also showed a positive correlation with the percentage change in TAS (r = 0.58, P < 0.01). AuAb-Ox-LDL levels decreased by 21.7% in patients with hypercholesterolemia and by 12.6% in patients with mixed-type hyperlipidemia. Also AuAb-Ox-LDL levels in patients with hypercholesterolemia were higher than in those with mixed-type hyperlipidemia (367 +/- 294 compared with 300 +/- 176 mU/l). CONCLUSION: It was concluded that lipid-lowering therapy may contribute to the reduction in levels of AuAb-Ox-LDL and the increase in the antioxidant capacity of plasma LDL and TAS. It was also suggested that the measurement of antibodies against Ox-LDL during lipid-lowering therapy may be used as an important marker for representing in-vivo LDL oxidation and atherosclerotic processes. SN - 0954-6928 UR - https://www.unboundmedicine.com/medline/citation/11917201/The_effects_of_lipid_lowering_therapy_on_low_density_lipoprotein_auto_antibodies:_relationship_with_low_density_lipoprotein_oxidation_and_plasma_total_antioxidant_status_ L2 - http://Insights.ovid.com/pubmed?pmid=11917201 DB - PRIME DP - Unbound Medicine ER -